Sacituzumab govitEcan in THYroid Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Differentiated Thyroid CancerAnaplastic Thyroid Cancer
Interventions
DRUG

Sacituzumab govitecan

Dose of 10 mg/kg intravenously

Trial Locations (11)

Unknown

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

NOT_YET_RECRUITING

Complexo Hospitalario Universitario de Ferrol, Ferrol

RECRUITING

Institut Catala d´Oncologia (ICO) -Hospitalet, Hospitalet de Llobregat (Barcelona)

RECRUITING

Hospital Clínico San Carlos, Madrid

RECRUITING

Hospital Universitario la Paz, Madrid

NOT_YET_RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

RECRUITING

MD Anderson Cancer Center Madrid, Madrid

RECRUITING

Hospital General Universitario Morales Meseguer, Murcia

RECRUITING

Hospital Universitario Central de Asturias, Oviedo

RECRUITING

H.U. Marqués de Valdecilla, Santander

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MFAR

OTHER

collaborator

Gilead Sciences

INDUSTRY

lead

Grupo Espanol de Tumores Neuroendocrinos

OTHER